BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS; MESEMS investigators. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 2021;20:917-29. [PMID: 34687636 DOI: 10.1016/S1474-4422(21)00301-X] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu P, Qian Y, Liu X, Zhu X, Zhang X, Lv Y, Xiang J. Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis. Front Immunol 2022;13:1096402. [PMID: 36685534 DOI: 10.3389/fimmu.2022.1096402] [Reference Citation Analysis]
2 Fossati V, Peruzzotti-Jametti L, Pluchino S. A neural stem-cell treatment for progressive multiple sclerosis. Nat Med 2023;29:27-8. [PMID: 36639562 DOI: 10.1038/s41591-022-02164-9] [Reference Citation Analysis]
3 . Mitteilungen der Deutschen Gesellschaft für Neurologie. DGNeurologie 2023;6. [ DOI: 10.1007/s42451-023-00546-y] [Reference Citation Analysis]
4 Cohen JA, Lublin FD, Lock C, Pelletier D, Chitnis T, Mehra M, Gothelf Y, Aricha R, Lindborg S, Lebovits C, Levy Y, Motamed Khorasani A, Kern R. Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Mult Scler 2023;29:92-106. [PMID: 36113170 DOI: 10.1177/13524585221122156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Isaković J, Šerer K, Barišić B, Mitrečić D. Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force? Front Bioeng Biotechnol 2023;11:1139359. [PMID: 36926687 DOI: 10.3389/fbioe.2023.1139359] [Reference Citation Analysis]
6 Zolfaghari Baghbadorani P, Rayati Damavandi A, Moradi S, Ahmadi M, Bemani P, Aria H, Mottedayyen H, Rayati Damavandi A, Eskandari N, Fathi F. Current advances in stem cell therapy in the treatment of multiple sclerosis. Reviews in the Neurosciences 2022;0. [DOI: 10.1515/revneuro-2022-0102] [Reference Citation Analysis]
7 Scharler C, Poupardin R, Ebner-peking P, Wolf M, Schreck C, Brachtl G, Cronemberger Andrade A, Krisch L, Daheron L, Schallmoser K, Jürchott K, Küchler J, Stachelscheid H, Volk H, Oostendorp RAJ, Strunk D. Extra-hematopoietic immunomodulatory role of the guanine-exchange factor DOCK2. Commun Biol 2022;5:1246. [DOI: 10.1038/s42003-022-04078-1] [Reference Citation Analysis]
8 Xun C, Deng H, Zhao J, Ge L, Hu Z. Mesenchymal stromal cell extracellular vesicles for multiple sclerosis in preclinical rodent models: A meta-analysis. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.972247] [Reference Citation Analysis]
9 Brittain G, Coles AJ, Giovannoni G, Muraro PA, Palace J, Petrie J, Roldan E, Scolding NJ, Snowden JA, Sharrack B. Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? Pract Neurol 2022:pn-2022-003531. [PMID: 36162855 DOI: 10.1136/pn-2022-003531] [Reference Citation Analysis]
10 Cao C, Zhang L, Liu F, Shen J. Therapeutic Benefits of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome: Potential Mechanisms and Challenges. J Inflamm Res 2022;15:5235-46. [PMID: 36120184 DOI: 10.2147/JIR.S372046] [Reference Citation Analysis]
11 Peruzzotti-Jametti L, Pluchino S. Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary. Mult Scler 2022;28:1328-9. [PMID: 35786043 DOI: 10.1177/13524585221097958] [Reference Citation Analysis]
12 Karussis D, Kassis I, Petrou P. Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES. Mult Scler 2022;28:1324-6. [PMID: 35786042 DOI: 10.1177/13524585211062173] [Reference Citation Analysis]
13 Uccelli A, Freedman MS. Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No. Mult Scler 2022;28:1326-8. [PMID: 35786044 DOI: 10.1177/13524585221095427] [Reference Citation Analysis]
14 Kvistad CE, Kråkenes T, Gjerde C, Mustafa K, Rekand T, Bø L. Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke - A Systematic Review and Meta-Analysis. Front Neurol 2022;13:891514. [PMID: 35711260 DOI: 10.3389/fneur.2022.891514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bezukladova S, Genchi A, Panina-Bordignon P, Martino G. Promoting exogenous repair in multiple sclerosis: myelin regeneration. Curr Opin Neurol 2022;35:313-8. [PMID: 35674074 DOI: 10.1097/WCO.0000000000001062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Magy L. Traitements de fond de la sclérose en plaques. État des lieux et perspectives. Bulletin de l'Académie Nationale de Médecine 2022;206:741-751. [DOI: 10.1016/j.banm.2022.01.031] [Reference Citation Analysis]
17 Zhang Y, Gu J, Wang X, Li L, Fu L, Wang D, Wang X, Han X. Opportunities and challenges: mesenchymal stem cells in the treatment of multiple sclerosis. Int J Neurosci 2022;:1-14. [PMID: 35579409 DOI: 10.1080/00207454.2022.2042690] [Reference Citation Analysis]
18 Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2022. [PMID: 35578014 DOI: 10.1038/s41409-022-01702-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Tang Y, Wu P, Li L, Xu W, Jiang J. Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases. Front Immunol 2022;13:880523. [DOI: 10.3389/fimmu.2022.880523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Achini‐gutzwiller FR, Snowden JA, Corbacioglu S, Greco R, Greco R, Alexander T, Snowden J, Badoglio M, Labopin M, Abinun M, Apte S, Arnold R, Domenech A, Brierley C, Burman J, Castilla‐llorente C, Cooper N, Daghia G, Daikeler T, Papa N, Vries‐bouwstra J, Farge D, Finke J, Hagglund H, Hawkey C, Henes J, Hiepe F, Jessop H, Kiely D, Kazmi M, Kirgizov K, Kramer E, Mancardi G, Marjanovic Z, Martin R, Martin T, Ma D, Moore J, Miller P, Muraro P, Oliveira M, Polushin A, Onida F, Simoes B, Puyade M, Resnick I, Ricart E, Rovira M, Saccardi R, Saif M, Sakellari I, Sharrack B, Snarski E, Scherer HU, Sossa C, Withers B, Wulffraat N, Zaccara E, Amrolia P, Ansari M, Balduzzi A, Corbacioglu S, Dalassier A, Dalle J, Diaz CH, Feuchtinger T, Locatelli F, Lucchini G, Galimard J, Vincent MG, Handgretinger R, Kleinschmidt K, Lawitschka A, Martinez AP, Peters C, Rocha V, Ruggeri A, Sedlacek P, Svec P, Toporski J, Yesilipek A; The EBMT Autoimmune Diseases (ADWP) and Paediatric Diseases (PDWP) Working Parties. Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. Br J Haematol. [DOI: 10.1111/bjh.18176] [Reference Citation Analysis]
21 Rice CM, Sarkar P, Walsh P, Owen D, Bidgood C, Smith P, Kane NM, Asghar S, Marks DI, Scolding NJ. Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis - A phase I extension study (SIAMMS II). Mult Scler Relat Disord 2022;61:103782. [PMID: 35397289 DOI: 10.1016/j.msard.2022.103782] [Reference Citation Analysis]
22 Scalabrino G. Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure. Biomedicines 2022;10:815. [DOI: 10.3390/biomedicines10040815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Berard JA, Freedman MS, Marrie RA, Marriott JJ, Atkins HL, Szwajcer D, Courtman DW, Thebault S, Walker LA. Mesenchymal Stem Cell Therapy and Cognition in MS: Preliminary Findings from a Phase II Clinical Trial. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103779] [Reference Citation Analysis]
24 Van den Bos J, Ouaamari YE, Wouters K, Cools N, Wens I. Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis. Biomolecules 2022;12:340. [PMID: 35204840 DOI: 10.3390/biom12020340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Tremblay F, Ansari Y, Remaud A, Freedman MS. Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis. Clinical Neurophysiology 2022. [DOI: 10.1016/j.clinph.2022.01.125] [Reference Citation Analysis]
26 Beck ES, Reich DS. Multiple sclerosis in 2021: progress against progression. Lancet Neurol 2022;21:12-3. [PMID: 34942123 DOI: 10.1016/S1474-4422(21)00417-8] [Reference Citation Analysis]
27 Hohlfeld R. Mesenchymal stem cells for multiple sclerosis: hype or hope? Lancet Neurol 2021;20:881-2. [PMID: 34687621 DOI: 10.1016/S1474-4422(21)00324-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]